drugset
drugset / Trial / NCT06476093

SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

NCT06476093 ↗

Recruiting 46 enrolled The First People's Hospital of Lianyungang
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.

Timeline

Start
2024-07-01
Primary completion
2026-12-31
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg Oral

Indications

metastatic malignant neoplasm in the brain non-small cell lung carcinoma